KRAS and cancer: Unlike NSCLC driven by other less frequent oncogenic drivers (e.g., EGFR, ALK, MET1, and ROS1) that significantly benefit from selective kinase inhibitors (Reck & Rabe, 2017), there are still no clinically approved therapies that specifically target KRAS‐mutant cancers (Cox et al, 2014).